Clinical features of treatment-naive patients with hepatitis B virus infection

Wu, Wei; Zhu, Yu; Yu, Chenbo; Yang, Shigui; Ruan, Bing; Chen, Yu; Li, Lanjuan

doi:10.1097/md.0000000000006660

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An estimated figure has shown that less than 5% of rural patients are able to afford 1 year of treatment as opposed to 40% of patients in more developed regions [29]. In addition to issues concerning accessibility and costs of treatment, Chinese patients in rural regions also have poor health awareness; many infected-individuals are unaware of their HBV infection until symptoms appear [31,32]. …”

Section: Discussionmentioning

confidence: 99%

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Liu

Farazi

et al. 2018

Global Health Action

View full text Add to dashboard Cite

Background: Globally, of the 248 million people chronically infected with the hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) have been approved for the treatment of chronic hepatitis B (CHB) in China. Objectives: The aims of this study were to determine rates of adherence to NUC therapy in patients with CHB, to identify the self-perceived barriers to adherence, and to examine the factors associated with adherence. Methods: Questionnaire-based interviews were administered among Chinese patients with CHB at hepatology clinics of a tertiary hospital in the city of Wuhan, China. Adults aged 18 years or older prescribed with NUCs were recruited and interviewed to complete a 27-item questionnaire in a private setting, and adherence was measured using the Morisky Medication Adherence Scale (MMAS-8). Results: Among 369 participants, only 16.5% had high adherence (score of 8), 32.2% had medium adherence (score of 6 to <8), and 51.2% were measured with low adherence (score of <6). A logistic regression model was used to determine the factors associated with medication adherence. Significant predictors of high adherence consisted of urban residency, non-cirrhotic status, not using prescribed pills other than HBV medications, and reminders from family members. The five most common reasons for skipping NUCs were that medication(s) are expensive (48.7%), forgetfulness (45.1%), have experienced or worry about potential side effects (19.8%), do not want others to know about my medication(s) usage (18.5%), and ran out of pills and do not have time to refill (15.9%). Conclusions: This study revealed that adherence rates to oral antiviral therapy were far from optimal. This finding should generate public attention, and it would be beneficial for interventional programs to target Chinese patients from rural regions, as well as patients with low socioeconomic status, cirrhosis, and taking multiple medications.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Liu

Farazi

et al. 2018

Global Health Action

View full text Add to dashboard Cite

show abstract

“…Second, a diminished estimated glomerular filtration rate, hypophosphatemia, hyperphosphaturia, and Fanconi syndrome have been reported in patients using TDF (11)(12)(13). Lastly, more than 50% of patients infected with CHB are between the ages of 40 and 59 years putting them at a high risk of bone and kidney injury (14).…”

Section: Introductionmentioning

confidence: 99%

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

et al. 2021

View full text Add to dashboard Cite

Tenofovir alafenamide (TAF) is one of the most potent first-line nucleot(s)ide analogs for treating chronic hepatitis B virus (HBV) infections. To date, no cases of TAF drug resistance and/or suboptimal response have been reported. To our knowledge, this is the first report of two adult male patients presenting a suboptimal response response to TAF monotherapy. Our study indicates long-term observations and extensive data are needed to further evaluate the efficacy and safety of TAF, and highlights the need for the development of robust novel direct-acting antivirals and immune therapies for HBV.

show abstract

Global importance of new treatment strategies to efforts to control hepatitis B virus

Forbes¹,

Lavoie²,

Satram

et al. 2023

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Clinical features of treatment-naive patients with hepatitis B virus infection

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 27 publications

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report

Global importance of new treatment strategies to efforts to control hepatitis B virus

Contact Info

Product

Resources

About